LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A EBIT

The latest EBIT for LFMDP is $-25M as of June 2026. That compares with $5.5M in the prior-year period — down 560.6% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's historical trend and sector peers before judging valuation or financial health.

Over the past year, LFMDP's EBIT moved from $5.5M to $-25M — a 560.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's operating scale or balance-sheet position.

Against Healthcare companies, LFMDP currently prints $-25M for EBIT, while the sector average sits near $23B. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at LifeMD- 8.875% PRF PERPETUAL USD 25 - Ser A's growth, margins, and balance sheet.

A EBIT figure of $-25M for LFMDP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting LFMDP's EBIT ($-25M), review year-over-year change from $5.5M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.